Pilar DeLaPuente

Pilar DeLaPuente

Assistant Professor

Surgery

Bio:

Dr. de la Puente has been researching novel tissue engineered culture models for regenerative medicine and mimicking the tumor microenvironment for over 10 years. She holds a PhD in Animal Medicine and Surgery focusing on biomedical engineering, tissue engineering, and regenerative medicine. Dr. De la Puente is interested on the role of tumor microenvironment (TME) in cancer progression, drug resistance and cancer immunology.


Research Interests:

The De la Puente lab is focused on the role of tumor microenvironment (TME) in cancer progression, drug resistance and cancer immunology. The TME is highly complex including stromal, immune, and endothelial cells, signaling molecules, oxygen tension, and the extracellular matrix. Classical two-dimensional (2D) cultures fail to provide an adequate model for the complexities of human tumors. Our lab is developing personalized 3D models of the tumor microenvironment in order to more accurately mimic cell-cell and cell-matrix interactions. Our lab currently focuses on developing three dimensional models of solid tumors for personalized medicine. Through these culture models, we hope to gain a deeper understanding of the role of the tumor microenvironment and their accessory cells during cancer progression, drug resistance and cancer immunology for each individual patient.


Education:

  • Ph D, Animal Medicine and Surgery, University of Salamanca, 2012
  • MS, Animal Medicine and Surgery, University of Leon, 2010
  • BS, Biology, University of Leon, 2008

Grants:

  • Patient-derived in vitro breast cancer model for personalized in vitro drug screening, Lush Prize. (2019 - 2019)
  • Role of tumor microenvironment of tumor progression, drug resistance and immune escape, NIH/NIGMS. (2018 - 2021)

Publications:

Citations listed below are presented in a standardized, modified format for display purposes only. They do not necessarily reflect the preferred style and conventions of the faculty member or discipline.

  • De la Puente, Pilar, Fettig, N, Luderer, M J., Jin, A, Shah, S, Muz, B, Kapoor, V, Goddu, S M., Salama, N N., Tsien, C, Thotala, D, Shoghi, K, Rogers, B, and Azab, A K.. Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors., 922-933. Vol. 107, Iss. 3. Journal of pharmaceutical sciences, 2018. (DOI: 10.1016/j.xphs.2017.10.042)
  • De la Puente, Pilar, Luderer, M J., Federico, C, Jin, A, Gilson, R C., Egbulefu, C, Alhallak, K, Shah, S, Muz, B, Sun, J, King, J, Kohnen, D, Salama, N N., Achilefu, S, Vij, R, and Azab, A K.. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma., 158-176. Vol. 270. Journal of controlled release : official journal of the Controlled Release Society, 2018. (DOI: 10.1016/j.jconrel.2017.11.045)
  • Muz, B, Kusdono, H D., Azab, F, De la Puente, Pilar, Federico, C, Fiala, M, Vij, R, Salama, N N., and Azab, A K.. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance., 2916-2925. Vol. 58, Iss. 12. Leukemia & lymphoma, 2017. (DOI: 10.1080/10428194.2017.1319052)
  • Muz, B, Azab, F, De la Puente, Pilar, Landesman, Y, and Azab, A K.. Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma., 632-640. Vol. 10, Iss. 4. Translational oncology, 2017. (DOI: 10.1016/j.tranon.2017.04.010)
  • De la Puente, Pilar, and Azab, A K.. Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma., 529-541. Vol. 98, Iss. 6. European journal of haematology, 2017. (DOI: 10.1111/ejh.12870)
  • Burwick, N, Zhang, M Y., De la Puente, Pilar, Azab, A K., Hyun, T S., Ruiz-Gutierrez, M, Sanchez-Bonilla, M, Nakamura, T, Delrow, J J., MacKay, V L., and Shimamura, A. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma., 23-32. Vol. 55. Leukemia research, 2017. (DOI: 10.1016/j.leukres.2017.01.007)
  • Luderer, M J., Muz, B, De la Puente, Pilar, Chavalmane, S, Kapoor, V, Marcelo, R, Biswas, P, Thotala, D, Rogers, B, and Azab, A K.. A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma., 2530-9. Vol. 33, Iss. 10. Pharmaceutical research, 2016. (DOI: 10.1007/s11095-016-1977-2)
  • De la Puente, Pilar, and Azab, A K.. 3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?, 1545-7. Vol. 12, Iss. 13. Future oncology (London, England), 2016. (DOI: 10.2217/fon-2016-0057)
  • De la Puente, Pilar, Quan, N, Hoo, R S., Muz, B, Gilson, R C., Luderer, M, King, J, Achilefu, S, Salama, N N., Vij, R, and Azab, A K.. Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma., e307-11. Vol. 101, Iss. 7. Haematologica, 2016. (DOI: 10.3324/haematol.2016.142190)
  • De la Puente, Pilar, Azab, F, Muz, B, Luderer, M, Arbiser, J, and Azab, A K.. Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma., 1677-86. Vol. 57, Iss. 7. Leukemia & lymphoma, 2016. (DOI: 10.3109/10428194.2015.1099645)
  • Muz, B, De la Puente, Pilar, Azab, F, Luderer, M J., King, J, Vij, R, and Azab, A K.. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma., 70-81. Vol. 173, Iss. 1. British journal of haematology, 2016. (DOI: 10.1111/bjh.13927)
  • De la Puente, Pilar, Muz, B, Jin, A, Azab, F, Luderer, M, Salama, N N., and Azab, A K.. MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma., e399. Vol. 6. Blood cancer journal, 2016. (DOI: 10.1038/bcj.2016.7)
  • Muz, B, De la Puente, Pilar, Azab, F, and Azab, A K.. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy., 83-92. Vol. 3. Hypoxia (Auckland, N.Z.), 2015. (DOI: 10.2147/HP.S93413)
  • De la Puente, Pilar, Muz, B, Gilson, R C., Azab, F, Luderer, M, King, J, Achilefu, S, Vij, R, and Azab, A K.. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma., 70-84. Vol. 73. Biomaterials, 2015. (DOI: 10.1016/j.biomaterials.2015.09.017)
  • De la Puente, Pilar, Weisberg, E, Muz, B, Nonami, A, Luderer, M, Stone, R M., Melo, J V., Griffin, J D., and Azab, A K.. Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.. Leukemia research, 2015. (DOI: 10.1016/j.leukres.2015.09.005)
  • Luderer, M J., De la Puente, Pilar, and Azab, A K.. Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy., 2824-36. Vol. 32, Iss. 9. Pharmaceutical research, 2015. (DOI: 10.1007/s11095-015-1718-y)
  • Kapoor, V, Khudanyan, A, De la Puente, Pilar, Campian, J, Hallahan, D E., Azab, A K., and Thotala, D. Stem Cell Transfusion Restores Immune Function in Radiation-Induced Lymphopenic C57BL/6 Mice., 3442-5. Vol. 75, Iss. 17. Cancer research, 2015. (DOI: 10.1158/0008-5472.CAN-15-1412)
  • Muz, B, De la Puente, Pilar, Azab, F, Ghobrial, I M., and Azab, A K.. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia., 263-72. Vol. 13, Iss. 2. Molecular cancer research : MCR, 2015. (DOI: 10.1158/1541-7786.MCR-14-0150)
  • Muz, B, Azab, F, De la Puente, Pilar, Rollins, S, Alvarez, R, Kawar, Z, and Azab, A K.. Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib., 417586. Vol. 2015. BioMed research international, 2015. (DOI: 10.1155/2015/417586)
  • Muz, B, De la Puente, Pilar, Azab, F, Luderer, M, and Azab, A K.. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells., e262. Vol. 4. Blood cancer journal, 2014. (DOI: 10.1038/bcj.2014.82)
  • De la Puente, Pilar, and Azab, A K.. Delivery systems for brachytherapy., 19-28. Vol. 192. Journal of controlled release : official journal of the Controlled Release Society, 2014. (DOI: 10.1016/j.jconrel.2014.06.057)
  • Muz, B, De la Puente, Pilar, Azab, F, Luderer, M, and Azab, A K.. The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies., 1347-54. Vol. 12, Iss. 10. Molecular cancer research : MCR, 2014. (DOI: 10.1158/1541-7786.MCR-14-0028)
  • Azab, F, Vali, S, Abraham, J, Potter, N, Muz, B, De la Puente, Pilar, Fiala, M, Paasch, J, Sultana, Z, Tyagi, A, Abbasi, T, Vij, R, and Azab, A K.. PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance., 89-101. Vol. 165, Iss. 1. British journal of haematology, 2014. (DOI: 10.1111/bjh.12734)
  • De la Puente, Pilar, and Ludeña, D. Cell culture in autologous fibrin scaffolds for applications in tissue engineering., 1-11. Vol. 322, Iss. 1. Experimental cell research, 2014. (DOI: 10.1016/j.yexcr.2013.12.017)
  • De la Puente, Pilar, Muz, B, Azab, F, Luderer, M, and Azab, A K.. Molecularly targeted therapies in multiple myeloma., 976567. Vol. 2014. Leukemia research and treatment, 2014. (DOI: 10.1155/2014/976567)
  • De la Puente, Pilar, and Azab, A K.. Contemporary drug therapies for multiple myeloma., 563-73. Vol. 49, Iss. 9. Drugs of today (Barcelona, Spain : 1998), 2013. (DOI: 10.1358/dot.2013.49.9.2020941)
  • De la Puente, Pilar, Muz, B, Azab, F, and Azab, A K.. Cell trafficking of endothelial progenitor cells in tumor progression., 3360-8. Vol. 19, Iss. 13. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. (DOI: 10.1158/1078-0432.CCR-13-0462)
  • De la Puente, Pilar, Ludeña, D, López, M, Ramos, J, and Iglesias, J. Differentiation within autologous fibrin scaffolds of porcine dermal cells with the mesenchymal stem cell phenotype., 144-52. Vol. 319, Iss. 3. Experimental cell research, 2013. (DOI: 10.1016/j.yexcr.2012.10.009)
  • De la Puente, Pilar, Ludeña, D, Fernández, A, Aranda, J L., Varela, G, and Iglesias, J. Autologous fibrin scaffolds cultured dermal fibroblasts and enriched with encapsulated bFGF for tissue engineering., 648-54. Vol. 99, Iss. 4. Journal of biomedical materials research. Part A, 2011. (DOI: 10.1002/jbm.a.33231)
  • Valero-Gomez, A, De la Puente, Pilar, and Hernando, M. Impact of two adjustable-autonomy models on the scalability of single-human/multiple-robot teams for exploration missions., 703-16. Vol. 53, Iss. 6. Human factors, 2011. (DOI: 10.1177/0018720811420427)

Awards and Honors:

  • 2018 Young Investigator Award, Lush Prize, 2018
  • Research Fellow Award, Multiple Myeloma Research Foundation (MMRF), 2015
  • ASH Abstract Achievement Award, American Society of Hematology, 2014
  • ASH Abstract Achievement Award, American Society of Hematology, 2013
  • Excellent Research Student (Cum Laude), School of Medicine, University of Salamanca, Spain, 2012
  • Excellent Research Student (Valedictorian), University of León, Spain., 2008

Presentations:

  • De la Puente, Pilar. Tissue engineered cultures and nanomedicine for cancer therapy.
  • De la Puente, Pilar. Tissue engineering for cancer immunology.
  • De la Puente, Pilar. Tissue engineering and targeted drug delivery approaches for regenerative medicine and cancer treatment.
  • De la Puente, Pilar. Cancer treatment: tissue engineering and targeted drug delivery.